http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/MONDO_0002046 MONDO_0002046

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/DRUGBANK:DB00657 DRUGBANK:DB00657

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/OffLabelIndication OffLabelIndication

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

https://pubmed.ncbi.nlm.nih.gov/30973369 pubmed.ncbi.nlm.nih.gov/30973369

0000-0002-7641-6446

2021-08-25T16:14:02.481Z

http://purl.org/np/RA2plesgmH... RA2plesgmH

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

The nicotinic-acetylcholine receptor (nAchR)- antagonist mecamylanine has been found to reduce the stimulus produced by ethanol in human lab studies. The nAchR-antagonist varenicline has also displayed positive effect in reducing alcohol consumption in multiple clinical trials. In this 12- week double-blind trial, participants (n 1⁄4 126) were randomized to either mecamylamine (10 mg daily) or placebo. No medication effect was found for reducing heavy drinking days (HDD) or alcohol craving. Smoking status had no effect on the results. The authors suggest that broad-spectrum nAchR-antagonists may not be beneficial in treat- ing AUD

0000-0002-7641-6446

2021-08-25T16:14:02.481Z